Listed by the USPTO as CUNNINGCHEN, KATHLEEN MARY
Tech Center 1600 • Art Units: 1641 1643 1646
This examiner grants 62% of resolved cases
CUNNINGCHEN, KATHLEEN MARY is assigned to Tech Center 1600 and art unit 1641. The profile covers 56 resolved cases, with an allowance rate of 62.5% and a median of 1456 days to allowance. The interview lift is 60.5%, the strongest recorded interview association in this profile and a significant factor for prosecution planning.
The listed companies are Zoetis LLC, Janssen Pharmaceuticals Inc., and Genentech Inc. The listed firms are LEE & HAYES, P.C., Casimir Jones, S.C., and Cermak & McGowan LLP. The limited case volume counsels against treating the figures as conclusive, but the interview measure supports early consideration of examiner discussion alongside carefully developed written responses.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18266053 | MUTATIONS IN FELINE ANTIBODY CONSTANT REGIONS | Final Rejection | Zoetis Services LLC |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | Non-Final OA | Genentech, Inc. |
| 17999352 | ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18551843 | COMPOSITIONS COMPRISING NKG2D, CXCR2, AND DAP10/DAP12 FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | King's College London |
| 17265934 | MODULATING PTPN2 TO INCREASE IMMUNE RESPONSES AND PERTURBING GENE EXPRESSION IN HEMATOPOIETIC STEM CELL LINEAGES | Non-Final OA | President and Fellows of Harvard College |
| 18155510 | HISTAMINE AND HRH1 SIGNALING ACTIVITY AS BIOMARKERS AND ASSOCIATED METHODS | Final Rejection | Board of Regents, The University of Texas System |
| 17625868 | ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREFOR | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17702648 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | Final Rejection | ACTINIUM PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.5% of resolved applications examined by Kathleen Mary Cunningchen were allowed (56 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +60.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kathleen Mary Cunningchen took 1,456 days on average from filing to allowance.
Kathleen Mary Cunningchen examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
